Werkgroep Cardiologische centra Nederland

VESALIUS-CV (Recruiting)

To evaluate the effect of treatment with evolocumab, compared with placebo, on risk for coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), or non-fatal or fatal ischemic stroke, whichever occurs first, in subjects with evidence of vascular disease without prior MI or stroke
Medicine
evolocumab
Population
ASCVD
Phase
III
Starting year
2018

Director of Study

drs. B.J.B. Hamer (Cardioloog)
Amersfoort, Meander Medisch Centrum